Amicus Therapeutics (FOLD) Competitors

Amicus Therapeutics (NASDAQ:FOLD) and Exact Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.

Which has higher valuation & earnings, FOLD or EXAS?

Amicus Therapeutics has higher earnings, but lower revenue than Exact Sciences. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$528.30M	4.19	-$151.58M	-$0.18	-40.00
Exact Sciences	$2.76B	3.07	-$204.15M	-$5.57	-8.19

Is FOLD or EXAS more profitable?

Amicus Therapeutics has a net margin of -10.62% compared to Exact Sciences' net margin of -37.29%. Amicus Therapeutics' return on equity of 12.44% beat Exact Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-10.62%	12.44%	2.60%
Exact Sciences	-37.29%	-5.29%	-2.45%

Do insiders and institutionals hold more shares of FOLD or EXAS?

88.8% of Exact Sciences shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 1.4% of Exact Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts recommend FOLD or EXAS?

Amicus Therapeutics presently has a consensus target price of $16.75, indicating a potential upside of 132.64%. Exact Sciences has a consensus target price of $69.25, indicating a potential upside of 51.86%. Given Amicus Therapeutics' higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Exact Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exact Sciences	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Does the MarketBeat Community favor FOLD or EXAS?

Exact Sciences received 459 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 73.14% of users gave Exact Sciences an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote.

Company	Underperform	Outperform
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%
Exact Sciences	Outperform Votes 991 73.14%	Underperform Votes 364 26.86%

Does the media prefer FOLD or EXAS?

In the previous week, Exact Sciences had 20 more articles in the media than Amicus Therapeutics. MarketBeat recorded 28 mentions for Exact Sciences and 8 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 0.91 beat Exact Sciences' score of 0.90 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exact Sciences	14 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more risk & volatility, FOLD or EXAS?

Amicus Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Summary

Exact Sciences beats Amicus Therapeutics on 10 of the 19 factors compared between the two stocks.